LPCN Lipocine Inc

$LPCN I won’t sell my shares. We all know biotech stocks will fly with positive results and Lipocine is working for them. Lower price is just an occasion to enter, add and reduce the average price. So, I’m sorry shorts, you won’t get my shares!

$LPCN There is now a real possibility that revenue from TLANDO, Lipocine's oral testosterone drug, may improve, because of major labeling changes made by the FDA. There used to be a Black Box warning about possible major cardiovascular events such as stroke and heart attack. The TRAVERSE clinical trial, which tested 5200 men, arrived at the conclusion that TRT, testosterone replacement therapy, was equivalent to a placebo in this type of risk. So no more Black Box warning. Additionally, prescriptions used to be limited to men with low testosterone for genetic reasons. Prescriptions for age-related low testosterone were considered "off label." That has changed now too. The FDA is now acknowledging that age-related TRT therapy is safe and effective.

$LPCN: Last week, $WFF surged from $2.05 to $4.18. Then shorts pushed it below $1.80. Isn't that a way similar to what's been happening with LPCN since last week? Now WFF is at $33.

$LPCN Q3 RESULTS ARE INSANE! TRAINWRECK FOR SHORTS!🔥 • CASH BOOM: Unaudited cash surged to $28.5M as of Nov 4! With only 8.24M shares out, pure cash value alone is $3.45/share. We are trading at a massive 60% discount to cash! No dilution risk! • REV EXPLOSION: Q3 revenue skyrocketed to $2.3M (vs $114K last year). Net loss cut to a tiny $0.08/share ($0.7M total). Lipocine is legally a hair away from operational break-even! • GLOBAL EXPANSION: Canada launch tracked for early 2027 + surprise new marketing approval in UAE under TESTYRA® with Pharmalink! • SECURE PIPELINE: FDA explicitly acknowledged NDA package for BRLIZIO™ (LPCN 1154) is complete, pending only this single Phase 3 BLOOM study. Tiny 4.64M free float is completely locked by insiders & institutions. Shorts are 100% trapped on the floor paying heavy borrow fees against a rock-solid balance sheet. This trading-below-cash distortion is officially over. Repricing starts NOW!🚀🌋 #ShortSqueeze #Value #Biotech

$LPCN I asked AI why it was taking so long to do the first dosing in BLOOM. AI correctly pointed out that the company had said early Q4, which it still is. AI also mentioned that the company is vetting the sites and patients with extreme care, to ensure a secure and accurate trial.

$LPCN well, if the Health Canada approved it, its not far to think FDA will to! Then this stock is 20$😀

$LPCN This stock now is like a crazy PRESSURE COOKER... between the crazy shorts situation and yesterday catalyst.. well if we push this a bare minimum is going higer than before with unbelivable snowball effect on the way up!!! 📈

$LPCN fu… king no brainer not to buy here . $28M cash on hand 13m MC and an fda approved drug. See you $3 in a month. When it run straight to$3in 1-2 days

$LPCN I spoke to Lipocine investor relations, they believe they have the email alerts fixed. We'll see when they announce the first patient dosed (next week)?

$LPCN 🚨 DO NOT LET THEM FOOL YOU🚨 Look closely at the tape right now. The smart money is absorbing every single share at these $1.80S levels while retail is blindly panic-selling 🤫🧠 Let’s be real about the math: ❌ US Market = Out-licensed to Halozyme years ago. Lipocine only got crumbs. Old news. ✅ CANADA Market = DIRECT exclusivity with Verity Pharma. Massive, direct cash injection straight into $LPCN’s bank account! 💰🇨🇦 Think about it: A totally VIRGIN market with OVER 700,000 annual prescriptions where patients have been begging for an oral pill to replace painful needles and messy gels. TLANDO has zero competition there now. 💊🔥 1️⃣ Short availability is mathematically at ABSOLUTE ZERO across primary broker feeds. 🔒 2️⃣ Volume has completely dried up on the dip because major funds are locked in and refuse to sell. 💎 3️⃣ The physical commercial launch is legally locked for BEFORE END OF YEAR. 🗓️

$LPCN very steady today after some volume mid morning. I have a feeling something is a foot.

$LPCN So um where did they get the 7M from? Overall thats great because thats means they def can complete the trail without having to raise cash

$LPCN I just took a quick look at the Biogen earnings report. It looks like Zurzuvae brought in 83.4m last quarter, pushing the total revenue for the first 9 months of 2026 to 209.4m. Nice to see the PPD market continuing to grow.

$LPCN The many months of stagnation around t $2 —with occasional upticks—should not make us forget that this stock is coming off a significant collapse earlier in the year. I mean… It has been disappointing long-term shareholders for more than just 2 weeks.

$LPCN The September announcement of a new Phase III trial, BLOOM, for LPCN 1154 marks a notable initiation (3). The results of this PPD candidate drug's previous Phase III trial, filed on April 2nd (1), caused or coincided with an extraordinary drop in the stock price. However, significant discrepancies were observed at one site in that trial's results. When that outlier site was excluded, the results showed strong effects at all time points, as presented at the ASCP Annual Meeting held in May (2). That is why the new trial is important. (1) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001535955/000149315226014834/form8-k.htm (2) https://www.sec.gov/Archives/edgar/data/1535955/000149315226025270/form8-k.htm (3) https://www.sec.gov/ix?doc=/Archives/edgar/data/0001535955/000149315226042466/form8-k.htm

$LPCN I am hardly a technical expert, but looking at Stock Consultant there does not appear to be any genuinely strong resistance until arond 1.99.

$LPCN Seems bullish at current SP Director John W. Higuchi open-market purchases: ~37,568 shares total across late September at ~$2.15–$2.23 (~$80K+). Significant insider buying earlier in 2026 as well (including by CEO Mahesh V. P

$LPCN creepy.. now i get scared a bit. Lets hope it is for the fear and no fundamental change we get surprised badly with

$LPCN i guess the news attracted traders that cratered the stock price. The shorters pushed the stock down. The traders still holding the stock that have no intention of being long-term investors are slowly giving up contributing to the slide. The true investor base isn't large enough to absorb all the downward pressure and push it back up to where it was.

$LPCN It seems unlikely. The volume is too low. They may have used some ATM capacity two days ago when the volume topped 100M. If so, hopefully there will be a filing soon to provide information on how much capacity is left. If they used most or all of it, any dilution effect is mitigated by the other side of the equation: the strengthening of the already robust cash position. It also removes a notable supply overhang and strengthens the holder base, as the WTD VWAP has exceeded and stayed above $3. The current low-volume decline is likely mostly attributable to short selling (in the last hour, 50k have been borrowed on IBKR; this is only one broker's data) and capital rotation into $WFF , as some holders may have opted to chase WFF with the aim of increasing their capital (if they succeed, more capital may return to LPCN). (Not advice, just inferences and probabilities)